Increased Donor‐Derived Cell‐Free DNA as a Predictor for the Early Detection of Antibody‐Mediated Rejection Following Heart Transplantation

Documenti analoghi

• Sirolimus Versus Mycophenolate Mofetil in Simultaneous Pancreas–Kidney Transplantation: Impact on Urinary Tract Infection Rates
  di: Barbora Píšová, et al.
  Pubblicazione: (2026)
• Donor‐Derived Cell‐Free DNA as a Marker for the Efficacy of Daratumumab in Patients With Antibody‐Mediated Rejection Post‐Heart Transplantation: A Case Series
  di: Anusha Konduri, et al.
  Pubblicazione: (2025)
• Daratumumab for Anti‐ HLA Antibody Desensitization and Antibody Mediated Rejection in Pediatric Heart Transplant Patients
  di: Caitlin Milligan, et al.
  Pubblicazione: (2025)
• Severe Flash Pulmonary Edema Following Rituximab and Daratumumab Infusion for Post‐Transplant Antibody‐Mediated Rejection
  di: Zeynab Rajabi, et al.
  Pubblicazione: (2025)
• Tocilizumab as Adjuvant Therapy in Refractory Antibody Mediated Rejection in Pediatric Kidney Transplant Recipients
  di: Anne M. Durkan, et al.
  Pubblicazione: (2025)